Anterogen Co., Ltd.

As of June 30, 2026, Anterogen Co., Ltd. carries a market capitalization of 210.63B, placing it among publicly traded companies globally. Its enterprise value stands at 167.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Anterogen Co., Ltd. has 10.01M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 25.16, and the price-to-book ratio stands at 2.62.

These figures are as of June 30, 2026. The EV/Sales ratio of 20.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 167.94B versus a market cap of 210.63B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Anterogen Co., Ltd. maintains a current ratio of 24.69, meaning it holds 24.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Anterogen Co., Ltd. posted a negative return on equity (ROE) of -1.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.85, reflecting losses generated across the asset base. The company generates approximately 267.82M in revenue per employee across its workforce of 31.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.31 indicates how many times Anterogen Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Anterogen Co., Ltd.'s stock has declined approximately 41.32% over the past 52 weeks. The 50-day moving average sits at 15,092.20, while the 200-day moving average is 29,134.05.

Over the twelve months ended June 30, 2026, Anterogen Co., Ltd. generated 8.37B in revenue and converted that into -1.62B in net income, yielding earnings per share of -161.67. EBITDA reached -1.88B, while operating income came in at -2.46B.

These figures are as of June 30, 2026. Total book value stands at 80.41B, with working capital of 46.82B providing operational flexibility.

Anterogen Co., Ltd. produced -1.11B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -331.57M in capital expenditures, free cash flow totaled -1.45B - equivalent to -144.49 per share.

Over the twelve months ended June 30, 2026, Anterogen Co., Ltd. posted a gross margin of 34.15, reflecting its pricing power and cost economics. The operating margin of -29.40 and net profit margin of -19.32 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Anterogen Co., Ltd. has an Altman Z-Score of 57.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.